Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study

Mean body weight change at 16 weeks was -6.0% for those receiving beinaglutide.

• Beinaglutide treatment was associated with a greater weight reduction compared to placebo, with a difference of -3.6%.
• 58.2% of patients on beinaglutide achieved a weight reduction of 5% or more, compared to 25.4% in the placebo group.
• 21.3% of patients on beinaglutide achieved a weight reduction of 10% or more, while only 5.1% in the placebo group reached this threshold.
• Beinaglutide led to a greater reduction in waist circumference, with a difference of -1.81 cm.
• Nausea was the most common adverse event reported in the beinaglutide group, affecting 49.3% of patients.

AI simplified